A phase III trial [15] demonstrated the superiority of TILs over ipilimumab (anti-CTLA-4) in patients with PD-1-resistant melanoma, with an improvement in median PFS from 3.1 to 7.2 months and median OS from 18.9 to 25.8 months. Here, CTLA4 is linked to melanoma.